Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

#SciChallenge2017 Deguelin’s Effect on Pancreatic Cancer Stem Cells

1,112 views

Published on

#SciChallenge2017
Tumors consist of cancerous stem cells, which is the smallest part of the tumor. No medication can directly effect these stem cells. In this study, our aim is to obstruct the spread of these stem cells and possibly eradicate them via apoptosis with the help of Deguelin.
According to the results of test subjects being exposed to Deguelin in different doses, the recovery process of pancreas patients can be sped up with different calculations.

Published in: Health & Medicine
  • Be the first to comment

#SciChallenge2017 Deguelin’s Effect on Pancreatic Cancer Stem Cells

  1. 1. DEGUELIN’S EFFECT ON PANCREATIC CANCER STEM CELLS Semra Ece Akat & Doga Dag Ozel Ege Lisesi, Turkey #SciChallenge2017
  2. 2. CONTENTS
  3. 3. PANCREATIC CANCER ℘ Pancreas cancer is a type of cancer that distrupts the digestive system and keeps the patiens away from eating food normally. It’s treatment is difficult and survival is minimal, therefore, it is considered as one of the most dangerous cancer types.
  4. 4. AIM OF THE PROJECT ℘ Tumors consist of cancerous stem cells, which is the smallest part of the tumor. No medication can directly effect these stem cells. In this study, our aim is to obstruct the spread of these stem cells and possibly eradicate them via apoptosis with the help of Deguelin. ℘ According to the results of test subjects being exposed to Deguelin in different doses, the recovery process of pancreas patients can be sped up with different calculations.
  5. 5. DEGUELIN ℘ It’s a natural compound made from the plant Mundulea sericea (C23H22O6). Its also used in insecticides. According to some studies, the compound enhances Deguelin’s anti- tumor activity.
  6. 6. PROCESS ℘ WST-I’s exhilaration percenteges were evaluated. With the result, the LD50 dose was specified. According to literature, the amount of doses were found as 0,1 - 0,5 - 2 - 10 - 25 µM and MA: 394,42 g/mol. With this, the doses for 5-FU and Deguelin were defined as 10 - 50 - 100 µM and 0,1 - 0,5 - 2 - 10 - 25 µM. ℘ The study was repeated at doses of 25-50-100-50 µM, when determined intervals increased the viability. Then, isolation of CD133+ Mia root cells, confirmation of CD133+ positivity by Flow Cytometry, and Annexin – PI dyeing procedures were performed respectively.
  7. 7. APOPTOSIS RESULTS Group Viability Early Apoptosis Late Apoptosis Necrosis Total Death Mia Control % 71,0 % 26,9 % 1,8 - % 28,7 GroupGroup ViabilityViability EarlyEarly ApoptosisApoptosis LateLate ApoptosisApoptosis NecrosisNecrosis TotalTotal DeathDeath Mia Total 100 µM Deguelin % 16,4 % 4,9 % 78 % 35,3 % 83,6 GroupGroup ViabilityViability EarlyEarly ApoptosisApoptosis LateLate ApoptosisApoptosis NecrosisNecrosis TotalTotal DeathDeath Mia Total 200 µM 5- FU % 49,8 % 5,0 % 42,6 % 10,4 % 50,2 GroupGroup ViabilityViability EarlyEarly ApoptosisApoptosis LateLate ApoptosisApoptosis NecrosisNecrosis TotalTotal DeathDeath Mia Total 100 µM Deguelin + 200 µM 5- % 11,6 % 69,5 % 16,4 - % 88,4
  8. 8. APOPTOSIS RESULTS Group Viability Early Apoptosis Late Apoptosis Necrosis Total Death Mia Total CD133+ Control % 86,7 % 11,2 % 0,3 - % 11,5 Group Viability Early Apoptosis Late Apoptosis Necrosis Total Death Mia CD133+ 100 µM Deguelin % 38,9 % 27,2 % 33,3 - % 61,1 Group Viability Early Apoptosis Late Apoptosis Necrosis Total Death Mia CD133+ 200 µM 5-FU % 34,1 % 31,2 % 33,9 - % 65,9
  9. 9. APOPTOSIS RESULTS Group Viability Early Apoptosis Late Apoptosis Necrosis Total Death Mia CD133+ 100 µM Deguelin + 200 µM 5-FU % 24,2 % 31,2 % 39,5 - % 75,8
  10. 10. RESULT ℘ Deguelin generates a vitro cytotxic effect in pancreatic cancer cells without the distortion of the 5-FU influence and CD133+ roots for apoptosis. Deguelin has proved successful in the treatment of pancreatic cancer when dosed alone at 100 µM, 5-FU 200 µM and dosed at 100 µM Deguelin + 200 µM 5-FU combined. ℘ In LD-50, better results were acquired when the two substance’s doses were combined than when they were used separately. % 49.2 viability was found and 100 µM was used in the making of the LD-50 dose for Deguelin, 200 µM and % 47.1 viability for 5-FU and ; % 45.5 viability in the combined dose.
  11. 11. EVALUATION ℘ We recommend combination of 200 μM 5-FU and 100 μM Deguelin because this dose has got more lethal effect than others. GroupGroup ActivityActivity EarlyEarly ApoptosisApoptosis LateLate ApoptosisApoptosis NecrosisNecrosis TotalTotal DeathDeath Mia Total 100 µM Deguelin + 200 µM 5-FU % 11,6 % 69,5 % 16,4 - % 88,4
  12. 12. APPLICABILITY ℘ With the use of Deguelin in pharmaceutical industry, we think that this will help pancreas patients slow down their cancerous stem cells if used as the amount specified.

×